Evidence map›Paper›PMID 37482512›Full record

Trial reportEuropean urology2023

Presurgical

Loïc Djaïleb, Wesley R Armstrong, Daniel Thompson, Andrei Gafita, Andrea Farolfi, Abhejit Rajagopal, Tristan R Grogan, Kathleen Nguyen, Matthias R Benz, Masatoshi Hotta and 16 more

3 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02611882 phase2completednot on this map

Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients

TypeinterventionalSponsorThomas HopeRan2015 to 2016Enrolled225ConditionsProstate CancerArmsGa-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
NCT02919111 phase2 / phase3completednot on this map

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2019Enrolled299ConditionsProstate CancerArmsGa-68 labeled PSMA-11 PET
NCT03368547 nacompletednot on this map

68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2016 to 2021Enrolled400ConditionsProstate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7ArmsComputed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Development and validation of a preoperativeEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Review
  4. PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  5. IntegratingCancers · 2025
    Article
  6. Review
  7. Hematological toxicity of [EJNMMI radiopharmacy and chemistry · 2025
    Article
  8. Review
  9. To see clear is not enough; it is the action that counts.Translational andrology and urology · 2024
    Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 9 institutions in 4 countries.

Loïc DjaïlebAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: ldjaileb@chu-grenoble.fr.
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; ULCA-Caltech Medical Scientist Training Program, David Geffen School of Medicine, Los Angeles, CA, USA.
Daniel ThompsonDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Andrei GafitaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Andrea FarolfiAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Abhejit RajagopalDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Tristan R GroganDepartment of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA.
Kathleen NguyenAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Matthias R BenzAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Department of Radiological Sciences, University of California Los Angeles, Los Angeles, CA, USA.
Masatoshi HottaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Francesco BarbatoDepartment of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Francesco CeciDivision of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
Sarah M SchwarzenböckDepartment of Nuclear Medicine, University Medical Centre, Rostock, Germany.
Marcus UnterrainerDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Helle D ZachoDepartment of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Roxanna JuarezDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Matthew CooperbergDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Peter CarrollDepartment of Urology, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Samuel WashingtonDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Robert E ReiterInstitute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Matthias EiberDepartment of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of California System · USAalborg University Hospital · DKAzienda USL di Bologna · ITEuropean Institute of Oncology · ITKlinikum rechts der Isar · DELMU Klinikum · DEUniversity of Rostock · DE

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Olujimi A Ajijola, David Wayne Dawson · 2024 to 2026
$5.3M
MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA235741NIGMS NIH HHS T32 GM152342
6 · The paper itself

Abstract

backgroundIn the initial staging of patients with high-risk prostate cancer (PCa), prostate-specific membrane antigen positron emission tomography (PSMA-PET) has been established as a front-line imaging modality. The increasing number of PSMA-PET scans performed in the primary staging setting might be associated with decreases in biochemical recurrence (BCR)-free survival (BCR-FS).

objectiveTo assess the added prognostic value of presurgical PSMA-PET for BCR-FS compared with the presurgical Cancer of the Prostate Risk Assessment (CAPRA) and postsurgical CAPRA-Surgery (CAPRA-S) scores in patients with intermediate- to high-risk PCa treated with radical prostatectomy (RP) and pelvic lymph node dissection. DESIGN, SETTING, AND

participantsThis is a follow-up study of the surgical cohort evaluated in the multicenter prospective phase 3 imaging trial (n = 277; NCT03368547, NCT02611882, and NCT02919111). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Each RESULTS AND LIMITATIONS: From December 2015 to December 2019, 277 patients underwent surgery after PSMA-PET. Clinical follow-up was obtained in 240/277 (87%) patients. The median follow-up after surgery was 32.4 (interquartile range 23.3-42.9) mo. Of 240 BCR events, 91 (38%) were observed. PSMA-PET N1/M1 was found in 41/240 (17%) patients. PSMA-PET prostate uptake, PSMA-PET N1/M1, and CAPRA and CAPRA-S scores were significant univariate predictors of BCR. The addition of PSMA-PET N1/M1 status to the presurgical CAPRA score improved the risk assessment for BCR significantly in comparison with the presurgical CAPRA score alone (c-statistic 0.70 [0.64-0.75] vs 0.63 [0.57-0.69]; p < 0.001). The C-index of the postsurgical model utilizing the postsurgical CAPRA-S score alone was not significantly different from the presurgical model combining the presurgical CAPRA score and PSMA-PET N1/M1 status (p = 0.19).

conclusionsPresurgical PSMA-PET was a strong prognostic biomarker improving BCR-FS risk assessment. Its implementation in the presurgical risk assessment with the CAPRA score improved the performance and reduced the difference with the reference standard (postsurgical CAPRA-S score). PATIENT SUMMARY: The use prostate-specific membrane antigen positron emission tomography improved the assessment of biochemical recurrence risk in patients with intermediate- and high-risk prostate cancer who were treated with radical prostatectomy and pelvic lymph node dissection.

Indexed as

Prostatic NeoplasmsFollow-Up StudiesGallium IsotopesGallium RadioisotopesHumansMalePositron-Emission TomographyPositron Emission Tomography Computed TomographyProspective StudiesProstatectomygallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesCancer of the Prostate Risk Assessment scoreCancer of the Prostate Risk Assessment—Surgery scorePelvic lymph node dissectionPrognostic valueProstate-specific membrane antigen positron emission tomographyRadical prostatectomy

Identifiers

PMID37482512
OpenAlexW4384944702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.